Chang et al. call for an end to the criminalisation of drug use and the enactment of a new reality based on solidarity and cooperation, to protect the health and restore of the rights and dignity of people who use drugs.
The Ana Liffey Drug Project and the LSE shed light on the positive impact of pragmatic, comprehensive and tailored responses to the challenges posed by the COVID-19 pandemic, particularly for people in situations of vulnerability.
The survey identifies a range of issues such as the access to health and harm reduction services and the ongoing negative impact of criminalisation, stigma and discrimination on the lives of people who use drugs.
Reprieve and LBHM discuss contradictions between development goals and punitive drug policies, and the negative impact on social, economic and environmental outcomes.
IDPC and TNI argue that the WHO’s recommendations will be an opportunity for African States to further decolonise drug control and strengthen the legal basis for emerging medicinal cannabis programmes.
HRI, SANPUD and Metzineres underscore the importance of alternatives to incarceration and the availability of humane, accessible and non-stigmatising services in prisons and the community.
Transform and MUCD compare different aspects of regulation models in Canadian provinces, including licences, retail stores, age restrictions, prices, home-growing and remaining social inequalities.
AIN states that by addressing the underlying causes of coca cultivation, collaborative coca crop reductions in Bolivia proved to be more sustainable than those achieved under forced eradication.
The 5th Brandenburg Forum offered a space for government, UN and civil society representatives to discuss the state of play of international drug policy as well as recent trends and developments.
EHRA's report highlights changes due to the pandemic for harm reduction services, including take-home OST medications, mobile outpatient clinics and the provision of food and shelter.
HRI and INPUD call on the international community to ensure the continuation of harm reduction services and prioritise community leadership to ensure people who use drugs are not left behind in the COVID-19 response.
